Biohaven Pharma Holding Company Ltd. acquired Channel Biosciences, LLC, a subsidiary of Knopp Biosciences, for $100 million to expand its portfolio in the treatment of epilepsy and other neurological disorders.

Deal-at-a-Glance
Acquirer:Biohaven Pharma Holding Company Ltd. (US)
Target:Channel Biosciences, LLC (US)
Value:$100 million
Type:Acquisition
Closed Date:February 25, 2022
Announced Date:February 25, 2022

The acquisition includes an upfront payment of $65 million in Biohaven common shares and $35 million in cash. The deal also features additional earnout payments up to $1.4 billion contingent upon the achievement of developmental and regulatory milestones.

Deal Mechanics

Biohaven acquired Channel Biosciences' Kv7 ion channel platform, which includes next-generation Kv7 channel activators for several target indications such as epilepsy, pain disorders, and affective disorders. The deal is structured to provide Biohaven with the rights to develop and commercialize these compounds.

Strategic Rationale

The acquisition of Channel Biosciences' Kv7 ion channel platform represents a strategic move by Biohaven to diversify its product pipeline in neuroscience, specifically targeting disorders that have significant unmet medical needs. The Kv7 technology holds promise for the treatment of epilepsy and other neurological conditions where current therapies are limited.

Financial Context

Biohaven's expansion into Kv7 channel activators complements its existing portfolio while offering potential future revenue streams through milestone payments, which can significantly bolster Biohaven's financial position as these compounds progress through development and regulatory phases.

Advisors

The transaction did not disclose buy-side or sell-side advisors nor the legal counsel involved for both parties.

Outlook

This acquisition is anticipated to enhance Biohaven's competitive position within the biotechnology sector by incorporating innovative Kv7 channel activators into its research and development programs. The deal strengthens Biohaven's pipeline and positions it better to address critical neurological diseases.